IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Annis Gardner Whiting Capital Advisors LLC

Key Points

• Annis Gardner Whiting Capital Advisors LLC significantly reduced its stake in IQVIA Holdings by 92.0% during the first quarter, leaving them with just 176 shares valued at $31,000.
• IQVIA recently reported earnings of $2.81 per share, surpassing analysts' expectations, with revenue up 5.3% year-over-year at $4.02 billion.
• The stock has received a consensus rating of "Moderate Buy" from analysts, with an average target price of $228.62, indicating positive growth expectations for the company.

Annis Gardner Whiting Capital Advisors LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 92.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 176 shares of the medical research company's stock after selling 2,012 shares during the quarter. Annis Gardner Whiting Capital Advisors LLC's holdings in IQVIA were worth $31,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Associated Banc Corp increased its holdings in IQVIA by 28.4% in the 1st quarter. Associated Banc Corp now owns 170,422 shares of the medical research company's stock valued at $30,045,000 after purchasing an additional 37,650 shares in the last quarter. Atria Wealth Solutions Inc. boosted its position in shares of IQVIA by 5.6% in the first quarter. Atria Wealth Solutions Inc. now owns 1,812 shares of the medical research company's stock worth $319,000 after buying an additional 96 shares during the period. ING Groep NV grew its stake in shares of IQVIA by 72.3% in the first quarter. ING Groep NV now owns 24,787 shares of the medical research company's stock valued at $4,370,000 after buying an additional 10,400 shares in the last quarter. Smithfield Trust Co raised its holdings in shares of IQVIA by 112.8% during the 1st quarter. Smithfield Trust Co now owns 583 shares of the medical research company's stock valued at $103,000 after buying an additional 309 shares during the period. Finally, Blair William & Co. IL raised its holdings in shares of IQVIA by 38.0% during the 1st quarter. Blair William & Co. IL now owns 7,925 shares of the medical research company's stock valued at $1,397,000 after buying an additional 2,183 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on IQV shares. Citigroup restated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Stock Performance

Shares of NYSE IQV traded up $1.03 during trading on Friday, reaching $179.98. The stock had a trading volume of 877,737 shares, compared to its average volume of 2,400,431. The firm's 50 day moving average price is $166.23 and its two-hundred day moving average price is $169.45. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The stock has a market cap of $30.60 billion, a PE ratio of 26.05, a P/E/G ratio of 1.96 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the company earned $2.64 earnings per share. The firm's revenue was up 5.3% compared to the same quarter last year. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.